866-997-4948(US-Canada Toll Free)

Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market

Published By :

GBI Research

Published Date : Sep 2011

Category :

Biotechnology

No. of Pages : 142 Pages


GBI Research, the leading business intelligence provider, has released its latest research, Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market, which provides insights regarding therapeutic proteins sales forecasts until 2017. Therapeutic proteins markets in the key geographies of the US, the top five EU countries, and Japan are also covered in the report. The report also includes details about therapeutic proteins R&D pipelines and potential future blockbuster products. 

The report provides in-depth analysis of the main therapeutic protein classes, which includes monoclonal antibodies, insulins, interferons, growth hormones, colony stimulating factors, erythropoietins and blood factors. Furthermore, it includes market forecasts for each therapeutic class. The report also explores the competitive landscape, with a competitive analysis of the top companies in the market. 

GBI Researchs analysis estimated the global therapeutic proteins market to be valued at $93billion in 2010, with a compound annual growth rate (CAGR) of 16.4% between 2002 and 2010. The market is forecast to grow at a CAGR of 6.2% between 2010 and 2017, to reach $141.5 billion in 2017. In-depth analysis in the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.

GBI Researchs analysis found the R&D pipeline for the therapeutic proteins market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that therapeutic proteins R&D activity will remain active for at least the next four to five years.

Scope

  • The report analyzes market characterization, pipeline analysis and the competitive landscape in the therapeutic proteins market.
  • Data and analysis of the therapeutic proteins market in the leading geographies of the world: the US, Europe and Rest of the World.
  • Annualized market data for the therapeutic proteins market from 2002 to 2010, with forecasts to 2017 for blood factors, colony stimulating factors, erythropoietins, human growth hormone, insulin, interferons and monoclonal antibodies.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes.
  • Key drivers and restraints that have had a significant impact on the market.
  • Competitive landscape of the global therapeutic proteins market, including benchmarking of the top companies. The key companies studied in this report are Pfizer, Merck/Schering-Plough, F. Hoffmann-La Roche, Eli Lilly, Sanofi, Johnson and Johnson, Novo Nordisk, Amgen, Biogen and Abbott.

Reasons to buy

The report will aid business development and help marketing executives strategizing product launches - 

  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
Table of Contents

1. Table of Contents

1.1. List of Tables
1.2. List of Figures

2. Therapeutic Proteins Market: Introduction
2.1. GBI Research Report Guidance

3. Therapeutic Proteins Market: Market Overview

3.1. Introduction
3.1.1. Drivers and Barriers

4. Therapeutic Proteins Market: Market Characterization
4.1. Market Size

5. Therapeutic Proteins Market: Geographical Landscape
5.1. Revenue Analysis by Geography
5.2. The US
5.2.1. Market Size
5.3. Europe
5.3.1. Market Size
5.4. ROW (Rest of the World)
5.4.1. Market Size

6. Therapeutic Proteins Market: Therapeutic Landscape
6.1. Introduction
6.2. Erythropoietins Market
6.2.1. Introduction
6.2.2. Market Size
6.2.3. Annual Cost of Treatment for Major Therapies
6.3. Blood Factors Market
6.3.1. Introduction
6.3.2. Market Size
6.3.3. Annual Cost of Treatment for Major Therapies
6.4. Interferons Market
6.4.1. Introduction
6.4.2. Market Size
6.4.3. Annual Cost of Treatment for Major Therapies
6.5. Monoclonal Antibodies Market
6.5.1. Introduction
6.5.2. Market Size
6.5.3. Annual Cost of Treatment for Major Therapies
6.6. Growth Hormones Market
6.6.1. Introduction
6.6.2. Market Size
6.6.3. Annual Cost of Treatment for Major Therapies
6.7. Insulin Market
6.7.1. Introduction
6.7.2. Market Size
6.7.3. Annual Cost of Treatment for Major Therapies
6.8. Colony Stimulating Factors Market
6.8.1. Introduction
6.8.2. Market Size
6.8.3. Annual Cost of Treatment for Major Therapies

7. Therapeutic Proteins Market: Pipeline Analysis
7.1. Introduction
7.2. Profiles of Promising Proteins in the Therapeutic Proteins Market
7.2.1. rhGAD65 (Diamyd)
7.2.2. DiaPep277
7.2.3. Otelixizumab
7.2.4. Oral-Lyn
7.2.5. NecLip-pdFVIII
7.2.6. OBI-1
7.2.7. NN7008
7.2.8. Long Acting rFactor VIII
7.2.9. Human-cl rhFVIII
7.2.10. Abthrax (raxibacumab)
7.2.11. Simponi (golimumab)

8. Therapeutic Proteins Market: Competitive Landscape

8.1. Evolving Competitive Landscape
8.2. Market Share Analysis
8.2.1. Major Companies
8.3. Competitive Profiling
8.3.1. Pfizer
8.3.2. Johnson & Johnson
8.3.3. Hoffmann-La Roche Ltd.
8.3.4. Merck & Co., Inc
8.3.5. Eli Lilly and Company
8.3.6. Abbott Laboratories
8.3.7. Sanofi
8.3.8. Novo Nordisk
8.3.9. Amgen
8.3.10. Biogen

9. Therapeutic Proteins Market - Strategic Consolidations
9.1. Therapeutic Proteins Market - Mergers and Acquisitions
9.1.1. M&A Deals by Year
9.1.2. M&A Deals by Value
9.1.3. M&A Deals by Drug Class
9.1.4. M&A Deals by Geography
9.1.5. Major M&A Deals
9.2. Global Therapeutic Proteins Market - Licensing Deals
9.2.1. Licensing Deals by Year
9.2.2. Licensing Deals by Value
9.2.3. Licensing Deals by Drug Class
9.2.4. Licensing Deals by Geography
9.2.5. Major Licensing Deals
9.3. Global Therapeutic Proteins Market - Co-Development Deals
9.3.1. Co-Development Deals by Year
9.3.2. Co-Development Deals by Value
9.3.3. Co-Development Deals by Drug Class
9.3.4. Co-Development Deals by Geography
9.3.5. Major Co-Development Deals

10. Global Therapeutic Proteins Market: Appendix
10.1. Market Definitions
10.2. Abbreviations
10.3. Research Methodology
10.3.1. Coverage
10.3.2. Secondary Research
10.3.3. Primary Research
10.4. Therapeutic Landscape
10.4.2. Market Size by Geography
10.5. Geographical Landscape
10.6. Pipeline Analysis
10.7. Competitive Landscape
10.7.1. Expert Panel Validation
10.8. Contact Us
10.9. Disclaimer
10.10. Sources

List of Table


Table 1: Therapeutic Proteins Market, Global Market, Historical Revenue ($bn), 2002-2010 14
Table 2: Therapeutic Proteins Market, Global Market, Revenue Forecasts ($bn), 2010-2017 14
Table 3: Therapeutic Proteins Market, the US, Historical Revenue ($bn), 2002-2010 15
Table 4: Therapeutic Proteins Market, the US, Revenue Forecasts ($bn), 2010-2017 15
Table 5: Therapeutic Proteins Market, Europe, Historical Revenue ($bn), 2002-2010 16
Table 6: Therapeutic Proteins Market, Europe, Revenue Forecasts ($bn), 2010-2017 16
Table 7: Therapeutic Proteins Market, ROW, Historical Revenue ($bn), 2002-2010 17
Table 8: Therapeutic Proteins Market, ROW, Revenue Forecasts ($bn), 2010-2017 17
Table 9: Erythropoietin Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 19
Table 10: Erythropoietin Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 19
Table 11: Erythropoietin Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 20
Table 12: Erythropoietin Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 20
Table 13: Erythropoietin Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 21
Table 14: Erythropoietin Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 21
Table 15: Erythropoietin Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 22
Table 16: Erythropoietin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 22
Table 17: Blood Factors Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 25
Table 18: Blood Factors Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 25
Table 19: Blood Factors Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 26
Table 20: Blood Factors Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 26
Table 21: Blood Factors Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 27
Table 22: Blood Factors Market Size Forecast, Europe, Revenue Forecasts ($bn), 2010-2017 27
Table 23: Blood Factors Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 28
Table 24: Blood Factors Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 28
Table 25: Interferons Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 31
Table 26: Interferons Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 31
Table 27: Interferons Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 32
Table 28: Interferons Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 32
Table 29: Interferons Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 33
Table 30: Interferons Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 33
Table 31: Interferons Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 34
Table 32: Interferons Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 34
Table 33: Monoclonal Antibody Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 37
Table 34: Monoclonal Antibody Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 37
Table 35: Monoclonal Antibody Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 38
Table 36: Monoclonal Antibody Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 38
Table 37: Monoclonal Antibody Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 39
Table 38: Monoclonal Antibody Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 39
Table 39: Monoclonal Antibody Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 40
Table 40: Monoclonal Antibody Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 40
Table 41: Growth Hormones Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 43
Table 42: Growth Hormones Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 43
Table 43: Growth Hormones Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 44
Table 44: Growth Hormones Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 44
Table 45: Growth Hormones Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 45
Table 46: Growth Hormones Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 45
Table 47: Growth Hormones Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 46
Table 48: Growth Hormones Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 46
Table 49: Insulin Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 49
Table 50: Insulin Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 49
Table 51: Insulin Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 50
Table 52: Insulin Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 50
Table 53: Insulin Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 51
Table 54: Insulin Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 51
Table 55: Insulin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2010 52
Table 56: Insulin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 52
Table 57: Colony Stimulating Factor Therapeutics Market, Global, Historical Revenue ($bn), 2002-2010 55
Table 58: Colony Stimulating Factor Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 55
Table 59: Colony Stimulating Factor Therapeutics Market, the US, Historical Revenue ($bn), 2002-2010 56
Table 60: Colony Stimulating Factor Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 56
Table 61: Colony Stimulating Factor Therapeutics Market, Europe, Historical Revenue ($bn), 2002-2010 57
Table 62: Colony Stimulating Factor Therapeutics Market, Europe, Revenue Forecasts ($bn), 2010-2017 57
Table 63: Colony Stimulating Factor Therapeutics Market, ROW, Historical Revenue ($bn), 2002-2010 58
Table 64: Colony Stimulating Factor Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 58
Table 65: Therapeutic Proteins Market, Global, Pfizer, Sales of Major Marketed Products, 2011 70
Table 66: Therapeutic Proteins Market, Global, Pfizer, Pipeline, Phase I Molecules, 2011 71
Table 67: Therapeutic Proteins Market, Global, Pfizer, Pipeline, Phase II Molecules, 2011 74
Table 68: Therapeutic Proteins Market, Global, Pfizer, Pipeline, Phase III Molecules, 2011 77
Table 69: Therapeutic Proteins Market, Global, Johnson & Johnson, Sales of Marketed Products, 2010 79
Table 70: Therapeutic Proteins Market, Global, Johnson & Johnson, Pipeline, Phase I Molecules, 2011 80
Table 71: Therapeutic Proteins Market, Global, Johnson & Johnson, Pipeline, Phase II Molecules, 2011 81
Table 72: Therapeutic Proteins Market, Global, Johnson & Johnson, Pipeline, Phase III Molecules, 2011 82
Table 73: Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, Sales of Marketed Products, 2010 83
Table 74: Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, Pipeline, Phase I Molecules, 2011 84
Table 75: Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, Pipeline, Phase II Molecules, 2011 85
Table 76: Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, Pipeline, Phase III Molecules, 2011 86
Table 77: Therapeutic Proteins Market, Global, Merck & Co., Sales of Marketed Products, 2010 87
Table 78: Therapeutic Proteins Market, Global, Merck & Co., Pipeline, Phase I Molecules, 2011 88
Table 79: Therapeutic Proteins Market, Global, Merck & Co., Pipeline, Phase II Molecules, 2011 91
Table 80: Therapeutic Proteins Market, Global, Merck & Co., Pipeline, Phase III Molecules, 2011 94
Table 81: Therapeutic Proteins Market, Global, Eli Lilly & Co., Sales of Marketed Products, 2010 96
Table 82: Therapeutic Proteins Market, Global, Eli Lilly & Co., Pipeline, Phase I Molecules, 2011 97
Table 83: Therapeutic Proteins Market, Global, Eli Lilly & Co., Pipeline, Phase II Molecules, 2011 98
Table 84: Therapeutic Proteins Market, Global, Eli Lilly & Co., Pipeline, Phase III Molecules, 2011 102
Table 85: Therapeutic Proteins Market, Global, Abbott Laboratories, Sales of Marketed Products, 2010 104
Table 86: Therapeutic Proteins Market, Global, Abbott Laboratories, Pipeline, Phase I Molecules, 2011 105
Table 87: Therapeutic Proteins Market, Global, Abbott Laboratories, Pipeline, Phase II Molecules, 2011 106
Table 88: Therapeutic Proteins Market, Global, Abbott Laboratories, Pipeline, Phase III Molecules, 2011 107
Table 89: Therapeutic Proteins Market, Global, Sanofi, Sales of Marketed Products, 2010 108
Table 90: Therapeutic Proteins Market, Global, Sanofi, Pipeline, Phase I Molecules, 2011 109
Table 91: Therapeutic Proteins Market, Global, Sanofi, Pipeline, Phase II Molecules, 2011 110
Table 92: Therapeutic Proteins Market, Global, Sanofi, Pipeline, Phase III Molecules, 2011 112
Table 93: Therapeutic Proteins Market, Global, Novo Nordisk, Sales of Marketed Products, 2010 114
Table 94: Therapeutic Proteins Market, Global, Novo Nordisk, Pipeline, Phase I Molecules, 2011 115
Table 95: Therapeutic Proteins Market, Global, Novo Nordisk, Pipeline, Phase II Molecules, 2011 115
Table 96: Therapeutic Proteins Market, Global, Novo Nordisk, Pipeline, Phase III Molecules, 2011 116
Table 97: Therapeutic Proteins Market, Global, Amgen, Sales of Marketed Products, 2010 117
Table 98: Therapeutic Proteins Market, Global, Amgen, Pipeline, Phase I Molecules, 2011 117
Table 99: Therapeutic Proteins Market, Global, Amgen, Pipeline, Phase II Molecules, 2011 118
Table 100:Therapeutic Proteins Market, Global, Amgen, Pipeline, Phase III Molecules, 2011 118
Table 101:Therapeutic Proteins Market, Global, Biogen Idec, Sales of Marketed Products, 2010 119
Table 102:Therapeutic Proteins Market, Global, Biogen Idec, Pipeline, Phase I Molecules, 2011 119
Table 103:Therapeutic Proteins Market, Global, Biogen Idec, Pipeline, Phase II Molecules, 2011 120
Table 104:Therapeutic Proteins Market, Global, Biogen Idec, Pipeline, Phase III Molecules, 2011 120
Table 105:Therapeutic Proteins Market, Strategic Consolidations, Major M&A Deals, 2011 124
Table 106:Therapeutic Proteins Market, Strategic Consolidations, Major Licensing Deals, 2011 129
Table 107:Therapeutic Proteins Market, Strategic Consolidations, Co-Development Deals by Geography (%), 2011 134

List of Chart


Figure 1: Therapeutic Proteins Market, Global, Market Drivers and Barriers, 2010-2017 12
Figure 2: Therapeutic Proteins Market, Global, Revenue Forecasts ($bn), 2002-2017 14
Figure 3: Therapeutic Proteins Market, the US, Revenue Forecast ($bn), 2002-2017 15
Figure 4: Therapeutic Proteins Market, Europe, Revenue Forecast ($bn), 2002-2017 16
Figure 5: Therapeutic Proteins Market, ROW, Revenue Forecast ($bn), 2002-2017 17
Figure 6: Therapeutic Proteins Market, Market Share by Revenue (%), 2010 18
Figure 7: Therapeutic Proteins Market, Erythropoietin Market Share by Revenue (%), 2010 18
Figure 8: Erythropoietin Therapeutics Market, Global, Revenue ($bn), 2002-2017 19
Figure 9: Erythropoietin Therapeutics Market, the US, Revenue Forecasts ($bn), 2010-2017 20
Figure 10: Erythropoietin Therapeutics Market, Europe, Revenue Forecasts ($bn), 2002-2017 21
Figure 11: Erythropoietin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2010-2017 22
Figure 12: Erythropoietin Therapeutics Market, Annual Cost of Treatment for Major Indications ($), 2010 23
Figure 13: Therapeutic Proteins Market, Blood Factors Market Share by Revenue (%), 2010 24
Figure 14: Blood Factors Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 25
Figure 15: Blood Factors Therapeutics Market, the US, Revenue Forecasts ($bn), 2002-2017 26
Figure 16: Blood Factors Market Size Forecast, Europe, Revenue Forecasts ($bn), 2002-2017 27
Figure 17: Blood Factors Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2017 28
Figure 18: Blood Factors Therapeutics Market, Annual Cost of Treatment for Major Indications ($), 2010 29
Figure 19: Therapeutic Proteins Market, Interferons Market Share by Revenue (%), 2010 30
Figure 20: Interferons Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 31
Figure 21: Interferons Therapeutics Market, the US, Revenue Forecasts ($bn), 2002-2017 32
Figure 22: Interferons Therapeutics Market, Europe, Revenue Forecasts ($bn), 2002-2017 33
Figure 23: Interferons Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2017 34
Figure 24: Inteferons Therapeutics Market, Annual Cost of Treatment, Interferon Beta and Alfa ($), 2010 35
Figure 25: Monoclonal Antibody Therapeutics Market, Global, Market Share by Revenue (%), 2010 36
Figure 26: Monoclonal Antibody Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 37
Figure 27: Monoclonal Antibody Therapeutics Market, the US, Revenue Forecasts ($bn), 2002-2017 38
Figure 28: Monoclonal Antibody Therapeutics Market, Europe, Revenue Forecasts ($bn), 2002-2017 39
Figure 29: Monoclonal Antibody Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2017 40
Figure 30: Monoclonal Antibodies Therapeutics Market, Annual Cost of Treatment ($), 2010 41
Figure 31: Growth Hormones Therapeutics Market, Global, Market Share by Revenue (%), 2010 42
Figure 32: Growth Hormones Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 43
Figure 33: Growth Hormones Therapeutics Market, the US, Revenue Forecasts ($bn), 2002-2017 44
Figure 34: Growth Hormones Therapeutics Market, Europe, Revenue Forecasts ($bn), 2002-2017 45
Figure 35: Growth Hormones Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2017 46
Figure 36: Growth Hormones Therapeutics Market, Annual Cost of Treatment ($), 2010 47
Figure 37: Insulin Therapeutics Market, Global, Market Share by Revenue (%), 2010 48
Figure 38: Insulin Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 49
Figure 39: Insulin Therapeutics Market, the US, Revenue Forecasts ($bn), 2002-2017 50
Figure 40: Insulin Therapeutics Market, Europe, Revenue Forecasts ($bn), 2002-2017 51
Figure 41: Insulin Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2017 52
Figure 42: Insulin Therapeutics Market, Annual Cost of Treatment ($), 2010 53
Figure 43: Colony Stimulating Factor Therapeutics Market, Global, Market Share by Revenue (%), 2010 54
Figure 44: Colony Stimulating Factor Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 55
Figure 45: Colony Stimulating Factor Therapeutics Market, the US, Revenue Forecasts ($bn), 2002-2017 56
Figure 46: Colony Stimulating Factor Therapeutics Market, Europe, Revenue Forecasts ($bn), 2002-2017 57
Figure 47: Colony Stimulating Factor Therapeutics Market, ROW, Revenue Forecasts ($bn), 2002-2017 58
Figure 48: Colony Stimulating Factor Therapeutics Market, Annual Cost of Treatment ($), 2010 59
Figure 49: Therapeutic Proteins Market, Global, Market Share Analysis by Company (%), 2010 69
Figure 50: Therapeutic Proteins Market, Global, Pfizer, SWOT Analysis, 2011 78
Figure 51: Therapeutic Proteins Market, Global, Johnson & Johnson, SWOT Analysis, 2011 82
Figure 52: Therapeutic Proteins Market, Global, Hoffmann-La-Roche Ltd, SWOT Analysis, 2011 86
Figure 53: Therapeutic Proteins Market, Global, Merck & Co., SWOT Analysis, 2011 95
Figure 54: Therapeutic Proteins Market, Global, Eli Lilly & Co., SWOT Analysis, 2011 103
Figure 55: Therapeutic Proteins Market, Global, Abbott Laboratories, SWOT Analysis, 2011 107
Figure 56: Therapeutic Proteins Market, Global, Sanofi, SWOT Analysis, 2011 113
Figure 57: Therapeutic Proteins Market, Global, Novo Nordisk, SWOT Analysis 116
Figure 58: Therapeutic Proteins Market, Global, Amgen, SWOT Analysis, 2011 118
Figure 59: Therapeutic Proteins Market, Global, Biogen Idec, SWOT Analysis, 2011 120
Figure 60: Therapeutic Proteins Market, Strategic Consolidations, M&A Deals by Year, 2011 121
Figure 61: Therapeutic Proteins Market, Strategic Consolidations, M&A Deals by Value (%), 2011 122
Figure 62: Therapeutic Proteins Market, Strategic Consolidations, M&A Deals by Drug Class (%), 2011 122
Figure 63: Therapeutic Proteins Market, Strategic Consolidations, M&A Deals by Geography (%), 2011 123
Figure 64: Therapeutic Proteins Market, Strategic Consolidations, Licensing Deals by Year, 2011 126
Figure 65: Therapeutic Proteins Market, Strategic Consolidations, Licensing Deals by Value (%), 2011 127
Figure 66: Therapeutic Proteins Market, Strategic Consolidations, Licensing Deals by Drug Class (%), 2011 128
Figure 67: Therapeutic Proteins Market, Strategic Consolidations, Licensing Deals by Geography (%), 2011 129
Figure 68: Therapeutic Proteins Market, Strategic Consolidations, Co-Development Deals by Year, 2011 132
Figure 69: Therapeutic Proteins Market, Strategic Consolidations, Co-Development Deals by Value (%), 2011 133
Figure 70: Therapeutic Proteins Market, Strategic Consolidations, Co-Development Deals by Drug Class (%), 2011 133
Figure 71: Therapeutic Proteins Market, Strategic Consolidations, Co-Development Deals by Geography (%), 2011 134
Figure 72: GBI Research Market Forecasting Model 140

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *